Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1049-1056

  Chiu, Shih Jiuan ^a   Marcucci, Guido ^a,b,c   Lee, Robert J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense delivery; Antisense oligodeoxyribonucleotide; Bcl2; Drug targeting; Folate receptor; G3139; Leukemia; Liposomes

Indexed keywords

ANTIINFECTIVE AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DAUNORUBICIN; FOLATE RECEPTOR; LIPOSOME; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; DAUNORUBICIN; DOWN-REGULATION; FOLIC ACID; HUMANS; KB CELLS; LIPOSOMES; MICROSCOPY, FLUORESCENCE; PARTICLE SIZE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CELL SURFACE; RNA, MESSENGER; THIONUCLEOTIDES;

EID: 33645829634     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Liu CM, Liu DP and Liang CC: Oligonucleotide-mediated gene repair at DNA level: the potential applications for gene therapy. J Mol Med 80(10): 620-628, 2002.
2. Shi FX and Hoekstra D: Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J Control Release 97(2): 189-209, 2004.
3. Bennett CF, Chiang MY, Chan HD, Shoemaker JEE and Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41(6): 1023-1033, 1992.
4. Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14-18) chromosome-translocation. Science 226(4678): 1097-1099, 1984.
5. Dias N and Stein CA: Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 54(3): 263-269, 2002.
6. Banerjee D: Technology evaluation: G-3139. Curr Opin Mol Ther 1(3): 404-408, 1999.
7. Cunningham D, Webb A and Cotter F: BCL-2 in lymphomas: from laboratory to clinic. Cancer Gene Ther 4(1): 66-66, 1997.
8. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng MZ and Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14(11): 1574-1578, 1996.
9. Douglas JT and Curiel DT: Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromusc Disord 7(5): 284-298, 1997.
10. Gottschalk S, Cristiano RJ, Smith LC and Woo SLC: Folate receptor-mediated DNA delivery into tumor-cells - potosomal disruption results in enhanced gene-expression. Gene Ther 1(3): 185-191, 1994.
11. Mislick KA, Baldeschwieler JD, Kayyem JF and Meade TJ: Transfection of folate-polylysine DNA complexes - evidence for lysosomal delivery. Bioconjug Chem 6(5): 512-515, 1995.
12. Guo WJ and Lee RJ: Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS J 1(4): article 19, 1999.
13. Leamon CP, Weigl D and Hendren RW: Folate copolymer-mediated transfection of cultured cells. Bioconjug Chem 10(6): 947-957, 1999.
14. Benns JM, Maheshwari A, Furgeson DY, Mahato RI and Kim SW: Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J Drug Target 9(2): 123-139, 2001.
15. Benns JM, Mahato RI and Kim SW: Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Control Release 79(1-3): 255-269, 2002.
16. Ward CM, Pechar M, Oupicky D, Ulbrich K and Seymour LW: Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J Gene Med 4(5): 536-547, 2002.
17. van Steenis JH, van Maarseveen EM, Verbaan FJ, Verrijk R, Crommelin DJA, Storm G and Hennink WE: Preparation and characterization of folate-targeted pEG-coated pDMAEMA-based polyplexes. J Control Release 87(1-3): 167-176, 2003.
18. Dauty E, Remy JS, Zuber G and Behr JP: Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 13(4): 831-839, 2002.
19. Hofland HEJ, Massen C, Iginla S, Osetinsky I, Reddy JA, Leamon CP, Scherman D, Bessodes M and Wils P: Folate-targeted gene transfer in vivo. Mol Ther 5(6): 739-744, 2002.
20. Lee RJ and Huang L: Folate-targeted, anionic liposome-entrapped polylysine- condensed DNA for tumor cell-specific gene transfer. J Biol Chem 271(14): 8481-8487, 1996.
21. Reddy JA, Dean D, Kennedy MD and Low PS: Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J Pharm Sci 88(11): 1112-1118, 1999.
22. Reddy JA and Low PS: Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release 64(1-3): 27-37, 2000.
23. Gosselin MA, Guo WJ and Lee RJ: Incorporation of reversibly cross-linked polyplexes into LPDII vectors for gene delivery. Bioconjug Chem 13(5): 1044-1053, 2002.
24. Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P and Leamon C: Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 9(22): 1542-1550, 2002.
25. Lee RJ and Low PS: Folate-mediated tumor-cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta-Biomembr 1233(2): 134-144, 1995.
26. Webb A, Cunningham D, Cotter F, Clarke PA, diStefano F, Ross P, Corbo M and Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349(9059): 1137-1141, 1997.
27. Gao X and Huang L: A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophy Res Comm 179(1): 280-285, 1991.
28. Maurer N, Wong KF, Stark H, Louie L, McIntosh D, Wong T, Scherrer P, Semple SC and Cullis PR: Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80(5): 2310-2326, 2001.
29. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ and Scherrer P: Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta-Biomembr 1510(1-2): 152-166, 2001.
30. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K and Pehamberger H: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728-1733, 2000.
31. Leamon CP and Reddy JA: Folate-targeted chemotherapy. Adv Drug Deliv Rev 56(8): 1127-1141, 2004.
32. Wang S, Lee RJ, Cauchon G, Gorenstein DG and Low PS: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth-factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene-glycol. Proc Natl Acad Sci USA 92(8): 3318-3322, 1995.
33. Yang LJ, Li J, Zhou W, Yuan X and Li S: Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells. J Control Release 95(2): 321-331, 2004.
34. Keller M, Jorgensen MR, Perouzel E and Miller AD: Thermodynamic aspects and biological profile of CDAN/DOPE and DC-Chol/DOPE lipoplexes. Biochemistry 42(20): 6067-6077, 2003.
35. Audouy S and Hoekstra D: Cationic lipid-mediated transfection in vitro and in vivo. Mol Membr Biol 18(2): 129-143, 2001.
36. Dass CR: Vehicles for oligonucleotide delivery to tumours. J Pharm Pharmacol 54(1): 3-27, 2002.
37. Shoji Y and Nakashima H: Current status of delivery systems to improve target efficacy of oligonucleotides. Curr Pharm Design 10(7): 785-796, 2004.
38. Pouton CW and Seymour LW: Key issues in non-viral gene delivery. Adv Drug Deliv Rev 46(1-3): 187-203, 2001.
39. Davis ME: Non-viral gene delivery systems. Curr Opin Biotechnol 13(2): 128-131, 2002.
40. Dass CR and Burton MA: Lipoplexes and tumours. A review. J Pharm Pharmacol 51(7): 755-770, 1999.
41. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C and Martin FJ: Sterically stabilized liposomes - improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88(24): 11460-11464, 1991.
42. Ahmad I, Longenecker M, Samuel J and Allen TM: Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung-cancer in mice. Cancer Res 53(7): 1484-1488, 1993.
43. Allen TM, Newman MS, Woodle MC, Mayhew E and Uster PS: Pharmacokinetics and antitumor-activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62(2): 199-204, 1995.
44. Stuart DD and Allen TM: A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta-Biomembr 1463(2): 219-229, 2000.
45. Kitada S, Takayama S, Deriel K, Tanaka S and Reed JC: Reversal of chemoresistance of lymphoma-cells by antisense-mediated reduction of Bcl-2 gene-expression. Antisense Res Dev 4(2): 71-79, 1994.
46. Keith FJ, Bradbury DA, Zhu YM and Russell NH: Inhibition of Bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 9(1): 131-138, 1995.
47. Ziegler A, Luedke GH, Fabbro D, Altmann KH and ZangemeisterWittke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89(14): 1027-1036, 1997.